VivoSeq
Hematology

Neutropenia

102

Pipeline Programs↗

13

Active Trials↗

46

Companies Involved↗

Neutropenia is a highly competitive landscape with 102 programs across 46 companies. The most active players are Enzon Pharmaceuticals, Inc., Tianjin SinoBiotech Ltd., Vicuron Pharmaceuticals. 27 therapies are approved with 21 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

11/100

Mech. Concentration

14/100

Completion Rate

68/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Enzon Pharmaceuticals, Inc.

2 programs

Phase 1T

Tianjin SinoBiotech Ltd.

1 program

Phase 1V

Vicuron Pharmaceuticals

1 program

Phase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

1 program

Phase 1E

Eastern Cooperative Oncology Group

2 programs

Phase 1A

Avyxa

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical14

Neulasta

Amgen

Filgrastim

Eastern Cooperative Oncology Group

Pegfilgrastim

Amgen

Itraconazole

Sebela Pharmaceuticals Development LLC

Zidovudine

Bp Consulting, Inc

Phase 110

Anidulafungin

Vicuron Pharmaceuticals

Sargramostim

Sanofi

Cefepime Hydrochloride

Jonsson Comprehensive Cancer Center

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

FK463

Astellas

Phase 230

Docetaxel

Avyxa

Cyclophosphamide

Baxter Healthcare Corporation

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Methylprednisolone

Pfizer

Cytarabine

Teva

Phase 321

Alcohol

Astellas

G-CSF

Arog Pharmaceuticals, Inc.

Daptomycin

Baxter Healthcare Corporation

Lipegfilgrastim

Merck & Co.

Nystatin

Good Molecules, LLC

Approved27

Amphotericin B

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Lithium Carbonate

Solvay Pharmaceuticals

Posaconazole

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Chlorhexidine

Dexcel Pharma Technologies Ltd.

Plerixafor

Genzyme, a Sanofi Company

Analysis

Modality Breakdown

83%

Small molecule

100 of 120 classified programs — the dominant modality here.

17%ALL OTHERSProtein / enzyme1916%Monoclonal antibody1<1%

Small molecule leads; the ring shows all 120 classified programs, each share of the total. Modality classified for 100% of 125 pipeline programs.

Analysis

Trial Status

105

clinical trials

Completed46 · 44%
Unknown status24 · 23%
Terminated15 · 14%
Recruiting7 · 7%
Withdrawn7 · 7%
Not yet recruiting5 · 5%
Other1 · 1%

Clinical Trials

Trial Activity

105 trials

Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor
Recruiting·—·N/A·NCT07096479·318 enrolled
Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance
Recruiting·—·Phase 4·NCT06293677·30 enrolled
Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection
Recruiting·HHebei Medical University Fourth Hospital·N/A·NCT07434063·200 enrolled
Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Recruiting·National Cancer Center, Korea·Phase 2·NCT06135896·98 enrolled
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Recruiting·HHenan Cancer Hospital·Phase 2·NCT07187908·1,076 enrolled
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens
Recruiting·BBeneficência Portuguesa de São Paulo·Phase 4·NCT06342115·176 enrolled
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
Recruiting·WWest Virginia University·Phase 2·NCT05537896·55 enrolled
Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy
Active, not recruiting·KKexing Biopharm Co., Ltd.·Phase 3·NCT06711523·250 enrolled
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
Not yet recruiting·—·Phase 2·NCT06926751·132 enrolled
BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
Not yet recruiting·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT07071844·162 enrolled
Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase
Not yet recruiting·GGadjah Mada University·Phase 4·NCT07320534·124 enrolled
Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia
Not yet recruiting·KKing Edward Medical University·Phase 4·NCT06988826·150 enrolled
A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06143735·99 enrolled
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Completed·WWake Forest University Health Sciences·Phase 1·NCT01484015·70 enrolled
Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia
Completed·OOttawa Hospital Research Institute·Phase 4·NCT02816112·458 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)